If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Cyramza ® (ramucirumab) injection
10 mg/mL solution
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
CYRAMZA® (ramucirumab): Indications for Use
Cyramza (ramucirumab) is indicated for the treatment of patients with gastric/GEJ adenocarcinoma, NSCLC, mCRC, and HCC.
Ramucirumab is a human VEGFR-2 antagonist indicated
-
as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or GEJ adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy
-
in combination with erlotinib, for first-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations
-
in combination with docetaxel, for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy
-
patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving ramucirumab
-
-
in combination with FOLFIRI, for the treatment of mCRC with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine, and
-
as a single agent, for the treatment of HCC in patients who have an AFP ≥400 ng/mL and have been treated with sorafenib.1
Enclosed Prescribing Information
CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly
1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
Glossary
AFP = alpha-fetoprotein
ALK = anaplastic lymphoma kinase
EGFR = epidermal growth factor receptor
FDA = Food and Drug Administration
FOLFIRI = irinotecan, folinic acid, and 5-fluorouracil
GEJ = gastroesophageal junction
HCC = hepatocellular carcinoma
mCRC = metastatic colorectal cancer
NSCLC = non-small cell lung cancer
VEGFR-2 = vascular endothelial growth factor receptor 2
Date of Last Review: May 05, 2020